PATENT CLAIM ANALYSIS

Application Number: 16065397
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "387000"]

Abstract:
Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

Claim (Index 41):
The compound of any of  claims 1 - 39 , wherein n is 0, 1 or 2.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.34783
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12666423', '15122863', '14061616', '16472185', '13897927']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.819314889382633
- 35 USC 102 Novelty (BERT): 0.5349147755118766
- Combined Prediction Score: 0.7908748779955573
- Mean Citation Score: 367.118278
- Max Citation Score: 369.48654
- Similarity Product: 203.54805822968245

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test